VERU INC. - COMMON STOCK

Veru Announces Proposed Public Offering of Common Stock

13 Dec 2023 16:01:28 By Nasdaq GlobeNewswire

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

04 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

26 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

20 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

11 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

30 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 Third Quarter Financial Results

10 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023

03 Aug 2023 08:30:01 By Nasdaq GlobeNewswire

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

21 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

01 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Jefferies Healthcare Conference

24 May 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 Second Quarter Financial Results

11 May 2023 06:30:00 By Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

04 May 2023 08:30:01 By Nasdaq GlobeNewswire

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

03 May 2023 08:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023

27 Apr 2023 06:45:00 By Nasdaq GlobeNewswire

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

20 Apr 2023 06:45:00 By Nasdaq GlobeNewswire

Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector

19 Apr 2023 08:30:20 By Nasdaq GlobeNewswire

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

11 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program

04 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

07 Mar 2023 08:30:00 By Nasdaq GlobeNewswire